Lyon, France – December 21, 2009 - genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today reports an important framework agreement with the Tufts University (Boston, USA).
Following an international competition, the company has been selected for a framework contract for a two years renewable period.
Under the terms of the agreement, researchers at the Tufts University, whose prestigious areas of study cover oncology, cardiovascular disease and virology (especially AIDS), will benefit from the expertise gained by genOway in transgenic technologies and technological innovations developed by the company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified mouse and rat models.
The financial terms of the agreement were not disclosed.
Alexandre Fraichard, CEO of genOway, declared: ‘We are very pleased to have signed this framework agreement with the prestigious Tufts University. This new contract adds to those signed in recent months with the most renowned U.S. universities like Pennsylvania University, Pittsburg University and the Harvard Medical School’s teaching hospital, BIDMC. The fact that these institutions, which employ some of the best scientific teams in the United States, chose our expertise and proprietary technologies makes us very proud. This improves our strong commercial dynamic and demonstrates that we offer our customers real innovations while responding to specific and diverse requests in oncology, virology, cardiovascular disease, metabolic disease or in neurosciences. And, above all, it demonstrates that these academic centers of excellence truly trust us and our work, in terms of the quality of our models, as well as our ability to meet development time objectives thanks to our efficient industrial processes.’
About Tufts University
Tufts University (Boston, USA) is one of the top ten U.S. Universities according to the classification established by the Princeton Review. The excellence of its research is internationally recognized and particularly in the fields of oncology, cardiovascular disease and virology (especially AIDS).
For more information please go to http://www.tufts.edu/
About genOway
genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company developing genetically modified and high value-added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, supplying more than 285 research institutes and bio-pharmaceutical companies. genOway is a leader in its market in terms of both size and customer portfolios. The company’s development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed many contracts with leaders of the pharmaceutical industry (Pfizer, Bayer, Boehringer Ingelheim, etc.), and with the most prestigious academic research centers (King’s College and the University of Manchester, in England; Duke University and the National Institutes of Health, in the United States; the Institut Pasteur, in France; NGFN and the Max Planck Institutes, in Germany, etc.).
To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents). For more information please go to www.genoway.com.
